Patents Examined by Karen Cochrane Carlson
  • Patent number: 11650201
    Abstract: The present invention relates to the field of anastasis, i.e., the process of reversal of apoptosis. More specifically, the present invention provides methods and compositions useful for studying anastasis. The present invention also provides a biosensor comprising (a) a split transcription factor complex comprising one half of a split transcription factor linked to a transmembrane domain via an enzyme cleavable linker; (b) a split transcription factor comprising the other half of the split transcription factor linked to a MTS via an enzyme-cleavable linker; and (c) a reporter system comprising (1) a first nucleic acid encoding a site specific recombinase operably linked to the site specific sequence for the transcription factor; and (2) a second nucleic acid comprising a stop codon cassette flanked by site specific recombination sequences, wherein the split transcription factor is Gal 4 or split Q. In other embodiments, the recombinase is Cre or FLP.
    Type: Grant
    Filed: November 16, 2017
    Date of Patent: May 16, 2023
    Assignee: The Johns Hopkins University
    Inventors: Ho Lam Tang, Ho Man Holly Tang
  • Patent number: 11649509
    Abstract: The present invention relates to the field of anastasis, i.e., the process of reversal of apoptosis. More specifically, the present invention provides methods and compositions useful for studying anastasis. In one embodiment, a tracking construct of the present invention comprises Lyn11-NES-ERT2-DEVD-rtTA-3xFLAG-DEVD-ERT2-NES. In another embodiment, a construct comprises Lyn11-NES-DEVD-rtTA-3xFLAG. In a further embodiment, a construct comprises ERT2-DEVD-rtTA-3XFLAG-DEVD-ERT2.
    Type: Grant
    Filed: November 16, 2018
    Date of Patent: May 16, 2023
    Assignee: The Johns Hopkins University
    Inventors: Ho Lam Hogan Tang, Ho Man Holly Tang
  • Patent number: 11643662
    Abstract: This disclosure relates to targeted protease compositions and uses related thereto. In certain embodiments, the disclosure relates to nanoparticles wherein a targeting molecule is linked to the nanoparticle and wherein a catalytic domain of a protease is linked to the nanoparticle. In certain embodiments, the targeting molecule and the catalytic domain are within a single polypeptide sequence. In certain embodiments, the targeting molecule binds a molecule more highly expressed on cancer cells then non-cancerous cells, and the nanoparticles disclosed herein are used for the treatment of cancer by further attaching an anti-cancer agent to the nanoparticle or incorporating an anticancer agent within the nanoparticle.
    Type: Grant
    Filed: June 10, 2019
    Date of Patent: May 9, 2023
    Assignee: Emory University
    Inventors: Lily Yang, Xiangxue Guo
  • Patent number: 11634476
    Abstract: The invention provides a method for culturing mammalian cells. The method provides greater control over cell growth to achieve high product titer cell cultures.
    Type: Grant
    Filed: September 11, 2020
    Date of Patent: April 25, 2023
    Assignee: AMGEN INC.
    Inventors: Brian D. Follstad, Rebecca E. McCoy, Arvia E. Morris
  • Patent number: 11623947
    Abstract: There is a need to provide a collagen powder having desirable product characteristics, such as high fluid absorption capacity, while also having processing characteristics that allow commercial manufacturing and handling of the collagen powder. The present invention relates to a collagen powder, a method of manufacture thereof, and uses thereof. In particular, the present invention relates to a process for preparing a collagen powder, the process comprising the steps of providing a collagen source; adjusting the concentration of the collagen source; adjusting the pH of the collagen source; freezing the collagen source; dehydrating the frozen collagen; and degrading the dehydrated collagen to a powder.
    Type: Grant
    Filed: April 8, 2013
    Date of Patent: April 11, 2023
    Assignee: Innocoll Pharmaceuticals Limited
    Inventors: Alexandra Dietrich, Michael Myers, Stefan Schneid
  • Patent number: 11622977
    Abstract: Materials and methods for producing genome-edited cells engineered to express a chimeric antigen receptor (CAR) construct on the cell surface, and materials and methods for genome editing to modulate the expression, function, or activity of one or more immuno-oncology related genes in a cell, and materials and methods for treating a patient using the genome-edited engineered cells.
    Type: Grant
    Filed: May 11, 2018
    Date of Patent: April 11, 2023
    Assignee: CRISPR THERAPEUTICS AG
    Inventors: Jonathan Alexander Terrett, Demetrios Kalaitzidis, Lawrence Klein
  • Patent number: 11608499
    Abstract: Methods for modification of target nucleic acids. The method involves a construct in which guide RNA is covalently linked to donor RNA (fusion NA) to be introduced into the target nucleic acid by homologous recombination and is based on the introduction of a nuclease, e.g. CRISPR or TALEN, into the cell containing the target nucleic acid. The fusion NA may be introduced as a DNA vector.
    Type: Grant
    Filed: April 20, 2017
    Date of Patent: March 21, 2023
    Assignee: BASF PLANT SCIENCE COMPANY GMBH
    Inventors: Leendert W. Neuteboom, John A. McElver, Rosa De Pinho Barroco, Chris De Wilde, Max Fabian Felle
  • Patent number: 11597894
    Abstract: The present disclosure relates to detergent compositions comprising subtilase variants exhibiting improved stability and/or improved wash performance in liquid detergent and methods for obtaining such detergent compositions. The variants are suitable for use in e.g. cleaning or detergent compositions, such as laundry detergent compositions and dish wash compositions, including automatic dish wash compositions.
    Type: Grant
    Filed: July 24, 2020
    Date of Patent: March 7, 2023
    Assignee: Henkel AG & Co. KGaA
    Inventors: Timothy O'Connell, Susanne Tondera, Hendrik Hellmuth, Thomas Weber, Rolf Thomas Lenhard, Signe Eskildsen Larsen, Miguel Duarte Guilherme Pereira Toscano, Esben Peter Friis, Astrid Munch, Mikael Bauer, Bena-Marie Lue
  • Patent number: 11578343
    Abstract: Some aspects of this disclosure provide compositions, methods, systems, and kits for controlling the activity of RNA-programmable endonucleases, such as Cas9, or for controlling the activity of proteins comprising a Cas9 variant fused to a functional effector domain, such as a nuclease, nickase, recombinase, deaminase, transcriptional activator, transcriptional repressor, or epigenetic modifying domain. For example, the inventive proteins provided comprise a ligand-dependent intein, the presence of which inhibits one or more activities of the protein (e.g., gRNA binding, enzymatic activity, target DNA binding). The binding of a ligand to the intein results in self-excision of the intein, restoring the activity of the protein.
    Type: Grant
    Filed: May 29, 2020
    Date of Patent: February 14, 2023
    Assignee: President and Fellows of Harvard College
    Inventors: David R. Liu, Kevin Davis
  • Patent number: 11579149
    Abstract: Bioluminescent biosensors useful for monitoring and/or quantifying, in vitro or in vivo, activity of the Hippo signaling pathway. The biosensors monitor LATS kinase activity or YAP-TEAD interaction. The biosensors may be used in methods for monitoring and/or quantifying in real-time, in vitro or in vivo, activity of the Hippo signaling pathway, wherein the activity may be LATS kinase activity and/or YAP-TEAD interaction. The biosensors may be provided in kits for monitoring and/or quantifying in real-time, in vitro or in vivo, activity of the Hippo signaling pathway, wherein the activity may be LATS kinase activity and/or YAP-TEAD interaction.
    Type: Grant
    Filed: November 1, 2018
    Date of Patent: February 14, 2023
    Assignee: Queen's University at Kingston
    Inventors: Xiaolong Yang, Taha Azad, Kazem Nouri
  • Patent number: 11572547
    Abstract: The present invention relates to fusion proteins which are capable of binding to phosphatidylserine comprising a phosphatidylserene binding ligand and a modified O6-alkylguanine-DNA alkyltransferase which is capable of autoconjugation to an O6-benzylguanine-modified label, the fusion proteins being capable of binding to phosphatidylserine on the surface of a cell undergoing apoptosis. The invention also relates to recombinant polypeptide precursors of the fusion proteins which comprise a secretion leader sequence, purification tag, protease cleavage site and the fusion protein. Also included in the scope of the invention are nucleic acids encoding the recombinant polypeptide precursor, vectors comprising the nucleic acids, host cells comprising the vectors, methods of production of the fusion proteins, kits and assays for detecting apoptosis.
    Type: Grant
    Filed: December 6, 2018
    Date of Patent: February 7, 2023
    Assignee: UNIVERSITY OF CAPE TOWN
    Inventors: Eden Padayachee, Fleury Augustin Nsole Biteghe, Olusiji Alex Akinrinmade, Sandra Jordaan, Stefan Barth
  • Patent number: 11559606
    Abstract: Methods and compositions for tissue regeneration of the present invention include a biocompatible porous composite of a decellularized tissue and an aptamer-functionalized hydrogel, wherein the aptamers of the aptamer-functionalized hydrogel specifically and reversibly bind to an active agent.
    Type: Grant
    Filed: December 11, 2017
    Date of Patent: January 24, 2023
    Assignee: The Penn State Research Foundation
    Inventors: Yong Wang, Xiaolong Zhang, Nan Zhao
  • Patent number: 11560578
    Abstract: Disclosed are methods for converting a first morphinan alkaloid compound into a second morphinan alkaloid compound in the presence of a neopinone isomerase enzyme under reaction conditions permitting the conversion of the first alkaloid compound into the second alkaloid compound. The first alkaloid compound can be neopinone or neomorphinone. The second alkaloid compound can be codeinone or morphinone. Related compositions are also disclosed.
    Type: Grant
    Filed: November 29, 2018
    Date of Patent: January 24, 2023
    Assignee: Antheia, Inc.
    Inventors: Peter J. Facchini, Xue Chen
  • Patent number: 11549104
    Abstract: The present invention relates to polypeptides having beta-glucanase activity, catalytic domains, beta-glucan binding domains and polynucleotides encoding the polypeptides, catalytic domains or beta-glucan binding domains. The invention also relates to nucleic acid constructs, vectors, and host cells comprising the polynucleotides as well as methods of producing and using the polypeptides, catalytic domains or beta-glucan binding domains. The invention further relates to cleaning or detergent compositions comprising polypeptides exhibiting beta-glucanase activity and one or more amylases and/or one or more proteases and uses thereof in cleaning or detergent applications and processes such as cleaning hard-surfaces, dish wash and laundering.
    Type: Grant
    Filed: December 7, 2016
    Date of Patent: January 10, 2023
    Assignee: NOVOZYMES A/S
    Inventors: Iben Damager, Morten Gjermansen, Carsten Andersen, Thomas Weber, Inga Kerstin Vockenroth, Clarissa Maisey, Astrid Spitz, Lisa-Marie Schütz, Claudia Ottow, Daniela Herbst, Claudia Lindner
  • Patent number: 11542523
    Abstract: An object of the present invention is to provide an animal cell with improved proliferation ability and survival rate, a method for producing the animal cell, and a method for producing a target protein formed of the animal cell. According to the present invention, there is provided an animal cell having a gene encoding a target protein and a foreign gene encoding an isovaleryl-CoA dehydrogenase, in which the isovaleryl-CoA dehydrogenase is overexpressed.
    Type: Grant
    Filed: June 10, 2020
    Date of Patent: January 3, 2023
    Assignee: FUJIFILM Corporation
    Inventors: Tatsuya Matsuura, Tsukasa Ishihara
  • Patent number: 11542305
    Abstract: Disclosed herein include methods, compositions, and kits suitable for use in detecting the activation level of a signal transducer. In some embodiments, there are provided synthetic protein circuits wherein recruitment of synthetic protein circuit components to an association location upon activation of a signal transducer generates an active effector protein. The effector protein can be configured to carry out a variety of functions when in an active state, such as, for example, inducing cell death. Methods of treating a disease or disorder characterized by aberrant signaling are provided in some embodiments.
    Type: Grant
    Filed: August 29, 2019
    Date of Patent: January 3, 2023
    Assignee: California Institute of Technology
    Inventors: Xiaojing Gao, Michael B. Elowitz
  • Patent number: 11534467
    Abstract: The invention encompasses compositions, kits and methods for modifying bacteria, preferably naturally occurring bacteria, in situ. These can be used to treat, prevent or cure microbiome-associated diseases or disorders by modulating the molecules expressed and/or secreted by bacterial populations of the microbiome in a specific manner. The genomic modifications can modify the interactions between part or all of these populations and the host in a way that decreases their deleterious potential on host health. The compositions, kits and methods of the invention do not result in the direct death of these populations or a direct significant inhibition of their growth. The invention further includes methods for screening for genetic modifications in the bacteria, for determining the efficiency of vectors at inducing these genetic mutations, and for determining the effects of these mutations on bacterial growth.
    Type: Grant
    Filed: April 8, 2022
    Date of Patent: December 27, 2022
    Assignee: Eligo Bioscience
    Inventors: Xavier Duportet, Antoine Decrulle, Cristina Del Carmen Gil-Cruz, Christian Ivan Pérez-Shibayama, Burkhard Ludewig, Jesus Fernandez Rodriguez, Andreas Brodel
  • Patent number: 11530403
    Abstract: The present invention discloses rapid and cost-effective method of de-glycosyation of a glycoprotein, wherein, glycoprotein is combined with anionic surfactant and reducing agent and non-ionic surfactant in order to obtain stable denatured glycoprotein. An endoglycosidase is further added to denatured glycoprotein to cleave N-linked glycans in order to obtain de-glycosylated protein. A rapid tool for assessing the protein conformation by partial de-glycosylation is also presented wherein the partial de-glycosylated protein is analysed using capillary electrophoresis (CE-SDS).
    Type: Grant
    Filed: November 17, 2017
    Date of Patent: December 20, 2022
    Assignee: BIOCON LIMITED
    Inventors: Anushikha Thakur, Seija Rohil, Shrivardhan Patil, Meenakshi Sudhakaran, Laxmi Adhikary
  • Patent number: 11530431
    Abstract: Methods for recombinant production of steviol glycoside and compositions containing steviol glycosides are provided by this invention.
    Type: Grant
    Filed: February 24, 2020
    Date of Patent: December 20, 2022
    Assignee: EVOLVA SA
    Inventors: Michael Dalgaard Mikkelsen, Jorgen Hansen, Ernesto Simon, Federico Brianza, Angelika Semmler, Kim Olsson, Simon Carlsen, Louis Düring, Alexei Ouspenski, Paula Hicks
  • Patent number: 11525148
    Abstract: This document relates to using bidirectional, multi-enzymatic scaffolds to biosynthesize cannabinoids in recombinant hosts.
    Type: Grant
    Filed: November 25, 2019
    Date of Patent: December 13, 2022
    Assignee: Khona Scientific Holdings, Inc.
    Inventor: Jordan Buck